Corneal Collagen Cross-Linking in the Treatment of Progressive Keratoconus: A Randomized Controlled Contralateral Eye Study Publisher Pubmed



Seyedian MA¹ ; Aliakbari S¹ ; Miraftab M¹ ; Hashemi H¹ ; Asgari S² ; Khabazkhoob M³ Show Affiliations
Source: Middle East African Journal of Ophthalmology Published:2015

Abstract

Background: To assess the short-term efficacy and safety of corneal collagen cross-linking (CXL) in preventing the progression of keratoconus (KCN). Materials and Methods: This randomized controlled clinical trial enrolled 26 patients diagnosed with bilateral progressive KCN and were eligible for CXL. In each patient, one eye was randomly selected for treatment, and the contralateral eye served as the control. The patients underwent CXL with riboflavin drops and ultraviolet radiation in the treated eye. One year follow-up data are presented. Postoperatively, patients were assessed for progression of KCN, visual changes, and other findings. The main outcome measures were maximum simulated keratometry (K-max), best spectacle-corrected visual acuity (BSCVA), and average simulated keratometry. P <0.05 was considered as statistically significant. Results: In the treated eyes, the mean K-max values decreased by 0.22 D at 1-year postoperatively and increased by 0.41 D in the control group. This difference was statistically significant (P < 0.001). BSCVA improved slightly (a decrease of 0.13 LogMAR) and decreased slightly in the control group (a 0.01 LogMAR increase). The difference between groups was statistically significant (P = 0.014). There was no decrease in visual acuity attributable to complications of CXL in the treated eyes. At 1-year, the keratometry in 3 (12%) treated eyes increased by more than 0.50 D and were considered cases of failed treatment. Conclusion: Preliminary and 1-year results indicate CXL can halt the progression of KCN in most cases without causing serious complications.